MedImmune Ventures

MedImmune Ventures was the corporate venture capital arm of MedImmune, a major biologics-focused biotechnology company that was acquired by AstraZeneca in 2007. The firm focused on investing in private companies that were developing innovative technologies and therapeutics across various stages of development, from seed to late-stage clinical trials. Its investment mandate covered a broad range of therapeutic areas, including oncology, infectious diseases, inflammation, and metabolic disorders, aligning with the strategic interests of its parent organization. In 2019, AstraZeneca retired the MedImmune brand and integrated its operations, including the venture capital functions, into the broader AstraZeneca corporate structure. Throughout its existence, MedImmune Ventures played a significant role in the biotech ecosystem by providing capital and strategic guidance to numerous successful startups.